Immuno-Oncology in Bladder Cancer: The Urologist's Role - Noah Hahn

In this lecture, Noah Hahn presents the importance of immuno-oncology (IO) - checkpoint inhibitors.  Patients with urothelial carcinoma are receiving approved immuno-oncologic drugs that significantly extend survival and are safer and more tolerable than chemotherapy. The efficacy of immuno-oncologic agents in advanced urothelial cancer has naturally raised questions about their potential use in earlier-stage disease. Could this approach achieve higher response rates and—most importantly—increase rates of cure for patients with muscle-invasive and non-muscle invasive
bladder cancer? The ongoing clinical trials are reviewed as are the results of the trials that have been recently completed.  


Biography:

Noah M. Hahn, MD, Associate Professor of Medicine, Department of Oncology and Urology, Johns Hopkins University School of Medicine
 

Read the Full Video Transcript